Clinical Trials Browser

Phase 1/2 × Cardiotoxicity × sulforaphane × Clear all

NCT03934905 2024-11-20

Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction

Phase 1/2 Recruiting

Cardiotoxicity